Sanofi India Limited share price
NSE: SANOFI · ISIN INE058A01010
Key numbers
- Market cap
- ₹ 7,232 Cr
- Current price
- ₹ 3,140.20
- 52-week high / low
- ₹ 4,900 / 3,049
- Stock P/E
- 21.7
- Book value
- ₹ 358.7
- Dividend yield
- 7.64%
- ROCE
- 54.2%
- ROE
- 40.3%
- Debt to equity
- 0.02
- Sales growth (3 yrs)
- -12.6%
- Profit growth (3 yrs)
- -19.3%
- 1-year return
- -37.2%
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 536 | 406 | 420 | 472 | 438 |
| Operating profit | 172 | 95 | 90 | 143 | 115 |
| Net profit | 120 | 70 | 62 | 103 | 84 |
| EPS (₹) | 51.89 | 30.18 | 26.79 | 44.55 | 36.26 |
Concall summary (2026-08-10)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- So, the Company remain strong, and we I hope that we continue to deliver on as per expectation.
- So, look, the 2%, yes, agreed that, it's not as per our expectation, but we are working with the partners, to see how they can, you know, reorganize, reinvest.
Growth & demand
- If you look at, we still continue to be a market leader, closer to 47% market share by value and volume acceleration of plus 6% with Lantus.
- And if you can look at the basal analog market share, which is, you know, which is the result of both Lantus and Toujeo, we have 58% value in the market share and close to 61% in the volume.
Margins & costs
- So, for this part of the opex, we focus only on the personnel cost - employee cost, and the other opex, because depreciation there is no and financial cost there is no major fluctuation.
- And delivering results today Sanofi India Limited August 05, 2026 really shows the strong execution, driving growth, significant margin expansion through operational excellence and alliances.
Capex & expansion
- And remember the public sector, which continues to grow, and the expansion into public sector, whether it's to CGHS, ESI, Railway, State, and Army, will continue helping us in terms of bringing the innovation into the access market.
Risks & challenges
- And we are facing certain challenge from Australia market where, heavy competition in this market for the mature products, but the good thing that, Sanofi India Limited August 05, 2026 the strategy that we put in place, we are offsetting a significant part of it.
- So, we are growing by 34% in terms of cash, no major risk that we're facing.
Peers in Drug Manufacturers - General
Data for information only, not investment advice. Prices end of day.